Atara Biotherapeutics Inc
ATRA12.050USD
-0.020-0.17%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
84.08MMarket Cap
14.51P/E TTM
More Details of Atara Biotherapeutics Inc Company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Company Info
Ticker SymbolATRA
Company nameAtara Biotherapeutics Inc
IPO dateOct 16, 2014
CEOMr. Anhco (Cokey) Nguyen, Ph.D.
Number of employees153
Security typeOrdinary Share
Fiscal year-endOct 16
Address1280 Rancho Conejo Blvd
CityTHOUSAND OAKS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91320
Phone18056234211
Websitehttps://www.atarabio.com/
Ticker SymbolATRA
IPO dateOct 16, 2014
CEOMr. Anhco (Cokey) Nguyen, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. Nachi Subramanian
Mr. Nachi Subramanian
Independent Director
Independent Director
--
--
Mr. James Huang
Mr. James Huang
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Panacea Venture
20.01%
Adiumentum Capital Fund I LP
18.30%
EcoR1 Capital, LLC
8.16%
Redmile Group, LLC
6.29%
The Vanguard Group, Inc.
2.72%
Other
44.53%
Shareholders
Shareholders
Proportion
Panacea Venture
20.01%
Adiumentum Capital Fund I LP
18.30%
EcoR1 Capital, LLC
8.16%
Redmile Group, LLC
6.29%
The Vanguard Group, Inc.
2.72%
Other
44.53%
Shareholder Types
Shareholders
Proportion
Venture Capital
20.01%
Investment Advisor/Hedge Fund
19.05%
Corporation
18.30%
Investment Advisor
4.22%
Individual Investor
2.90%
Hedge Fund
1.92%
Research Firm
0.44%
Bank and Trust
0.10%
Other
33.08%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
241
4.91M
73.40%
-1.70M
2025Q1
282
4.01M
65.40%
-1.34M
2024Q4
299
3.71M
64.35%
-1.71M
2024Q3
318
3.77M
66.12%
-1.71M
2024Q2
338
3.34M
67.67%
-2.05M
2024Q1
355
3.52M
73.26%
-1.12M
2023Q4
356
2.78M
67.54%
-1.84M
2023Q3
355
3.69M
90.14%
-612.93K
2023Q2
363
3.86M
98.31%
-820.50K
2023Q1
367
4.34M
112.70%
-175.57K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Panacea Venture
1.33M
19.88%
+780.66K
+141.94%
May 16, 2025
Adiumentum Capital Fund I LP
1.28M
19.2%
+151.14K
+13.33%
May 16, 2025
EcoR1 Capital, LLC
573.18K
8.56%
+41.05K
+7.71%
Mar 31, 2025
Redmile Group, LLC
441.70K
6.6%
--
--
May 16, 2025
The Vanguard Group, Inc.
190.76K
2.85%
+11.98K
+6.70%
Mar 31, 2025
Vestal Point Capital, LP
94.08K
1.41%
-30.91K
-24.73%
Mar 31, 2025
Staley Capital Advisers, Inc.
80.00K
1.2%
+30.00K
+60.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
56.01K
0.84%
--
--
Mar 31, 2025
Acadian Asset Management LLC
115.11K
1.72%
-9.36K
-7.52%
Mar 31, 2025
Geode Capital Management, L.L.C.
58.68K
0.88%
+3.94K
+7.19%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Date
Type
Ratio
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
